Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has completed dosing
View HTML
Toggle Summary Aldeyra Therapeutics Announces Development Programs at 2018 Research Day
Expanded Pipeline Features Distinct Mechanisms of Action Across Five Product Candidates Three Additional Clinical Programs Planned for 2019 LEXINGTON, Mass. , June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of
View HTML
Toggle Summary Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes
LEXINGTON, Mass. , June 25, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the Company was added to the
View HTML
Toggle Summary Aldeyra Therapeutics Announces 2018 Research Day
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research Day to
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc.  (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the first quarter
View HTML
Toggle Summary Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
LEXINGTON, Mass. , May 10, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to the newly
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will issue financial results for the quarter ended March
View HTML
Toggle Summary Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and SymptomsSafety and Tolerability Consistent with Standard of Care
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
LEXINGTON, Mass. , April 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the first patient in a
View HTML
Toggle Summary Aldeyra Therapeutics Announces Year End 2017 Financial Results
LEXINGTON, Mass. , March 29, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced financial results for the year ended
View HTML